0001815442 2026-02-25 2026-02-25 0001815442 1 2026-02-25 2026-02-25 0001815442 1 2026-02-25 2026-02-25 0001815442 2 2026-02-25 2026-02-25 iso4217:USD pure shares S-3 424B5 EX-FILING FEES 333-282912 0001815442 Kymera Therapeutics, Inc. N/A true false S-3 Kymera Therapeutics, Inc. false Equity Common Stock, $0.0001 par value true 500000000 500000000.00 0.0001381 69050.00 500000000.00 69050.00 0.00 27389.08 41660.92 The proposed maximum aggregate offering price is being used to calculate the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the "Securities Act").The total fee offsets are calculated in accordance with Rule 456(b) of the Securities Act. This "Calculation of Registration Fee" table shall be deemed to update the "Calculation of Registration Fee" table in the registrant's registration statement on Form S-3ASR filed with the Securities and Exchange Commission on October 31, 2024 (File No. 333-282912). Pursuant to Rule 457(p) under the Securities Act, the registrant hereby applies $27,389.08 of the registration fee previously paid in connection with the 2024 ATM Prospectus (as defined below) to offset the registration fees that are payable in connection with the registration of securities on this registration statement. true Kymera Therapeutics, Inc. S-3 333-282912 2024-10-31 27389.08 Equity Common Stock 300000000.00 true Kymera Therapeutics, Inc. S-3 333-282912 2024-10-31 27389.08 On October 31, 2024, the registrant filed a registration statement on Form S-3 (File No. 333-282912), including a prospectus in connection with its 2024 "at-the-market" offering program (the "2024 ATM Prospectus"). The registrant paid a filing fee in the amount of $27,389.08 to register shares of its common stock with a maximum aggregate offering price of $300,000,000, which fee was calculated pursuant to Rule 457(o) under the Securities Act. The offering pursuant to the 2024 ATM Prospectus has terminated. As of the termination of the offering made pursuant to the 2024 ATM Prospectus, $300,000,000 of shares of the registrant's common stock remained unsold. Pursuant to Rule 457(p) under the Securities Act, filing fees in the amount of $27,389.08 relating to the unsold securities are being carried forward. 500000000.00 true